genOway

📢 We will be participating to the upcoming Society for Immunotherapy of Cancer (SITC) meeting in Houston, TX from 6-10 November, 2024 👉 https://lnkd.in/eabsGCmN Our team of Scientific Business Developers and Experts would be thrilled to meet you at booth #647 to discuss how our preclinical solutions could help you in your research needs. If you’d like to book a 1-on-1 meeting, please contact us here 👉 https://lnkd.in/euwu4Ga3 To learn more on our preclinical models, stop by one of our three poster presentations on: 📅 Friday, 8 November 👉 Poster #937: ‘Tumor microenvironment composition is shaped by tumor cell line-derived xenograft subtype and tumor burden in BRGSF-HIS mice’ 👉 Poster #877: ‘Assessment of γδ T-cell therapies in humanized mice’ 📅 Saturday, 9 November 👉Poster #1446: ‘Novel FcγR humanized mouse models enabling efficacy and PK/PD of therapeutic antibodies’ Don't miss this opportunity to meet us!   #sitc2024 #preclinicalresearch #preclinicalservices

📢 We will be at the 1st In Vivo Preclinical Cancer Models workshop in Miami, FL from October 25-26, 2024 👉 https://lnkd.in/gJwga-UE On Saturday, October 26, 2024 at 8:35 a.m. EDT, Kader Thiam, our Senior Vice President - Discovery, Preclinical Models and Services, will give a presentation titled "BRGSF-HIS mouse model supporting in vivo cancer modeling and safety studies" ▶ Functional immune response involving both myeloid and lymphoid compartments ▶ BRGSF-HIS as recipient for PDX engraftment and therapies assessment ▶ Assessment of compound safety in BRGSF-HIS ▶ Find out more about our #BRGSF-HIS mouse model here 👉 https://lnkd.in/gUfAx92u #preclinicalmodels #cancerresearch #preclinicalresearch

In our poster unveiled at #AACR2024, we demonstrated that an anti-CD20 antibody depleted B cells in the humanized FcγR mouse model, while its silenced Fc variant did not 👉 https://lnkd.in/eJw4irri The new humanized FcγR mouse model enables a translatable assessment the Fc-mediated function of therapeutic antibodies 👉 https://lnkd.in/ezKwdc5E Efficacy data was generated in collaboration with over 10 biopharma partners, including argenx, Seismic Therapeutic and Innate Pharma, in the field of autoimmunity and immuno-oncology 👉 https://lnkd.in/epXUmS3z #preclinicalservices #preclinicalresearch #preclinicalmodels

In our poster unveiled at #AACR2024 genOway and Innate Pharma demonstrated an increased ADCC in the hFcγR model following treatment with Obitunuzumab, an antibody engineered to display enhanced Fc binding, relative to Rituximab, a monoclonal antibody with a regular hIgG1 Fc 👉 https://lnkd.in/e5-wvABR     The new humanized FcγR mouse model enables a translatable assessment the Fc-mediated function of therapeutic antibodies 👉 https://lnkd.in/ezKwdc5E   Efficacy data was generated in collaboration with over 10 biopharma partners, including argenx, Seismic Therapeutic and Innate Pharma, in the field of autoimmunity and immuno-oncology 👉 https://lnkd.in/epXUmS3z #preclinicalservices #preclinicalresearch #preclinicalmodels

The new humanized FcγR mouse model enables a translatable assessment the Fc-mediated function of therapeutic antibodies 👉 https://lnkd.in/ezKwdc5E Efficacy data was generated in collaboration with over 10 biopharma partners, including argenx, Seismic Therapeutic and Innate Pharma, in the field of autoimmunity and immuno-oncology. ✔️ In our poster unveiled at #AACR2024, genOway and Innate Pharma showed that the levels of NK cell-mediated ADCC observed in hFcγR NK cells are higher compared to NK cells from WT mice after treatment with Rituximab, a monoclonal antibody with a regular hIgG1 Fc 👉 https://lnkd.in/e5-wvABR   #preclinicalservices #preclinicalresearch #preclinicalmodels

🔬 We will be attending the 6th Macrophage-Directed Therapies Summit 2024 in Boston, MA from October 1-3, 2024! 👉 https://lnkd.in/ejDm6xDJ On Thursday, October 3, 2024 at 9:30 a.m. EDT, Kader Thiam, our Senior Vice President - Discovery, Preclinical Models and Services, will give a presentation titled "How to enhance translatability of myeloid-targeted therapies in preclinical models" The presentation will focus on: ▶ #BRGSF-HIS mouse: the only CD34+-reconstituted model with functional human lymphoid and myeloid compartments without side effects ▶ Myeloid cells functionality and assessment of immune modulation induced by biologics in the model ▶ Safety studies in the BRGSF-HIS model to investigate immune-related adverse effects Read more on the BRGSF-HIS model here 👉 https://lnkd.in/eUav-Ra5 #macrophagedirectedtherapiessummit #preclinicalmodels #cancerresearch 

🙏 Thanks to Institut de Biologie Structurale (IBS) for giving us the opportunity to present our concrete actions and results to reduce our total GHG emissions (scope 1, 2 and 3): -15% in 2 years while keeping a +50% growth! 👀 Watch José VIÑUELAS’ presentation 'Decarbonizing Preclinical R&D. Feedback session' here 👉 https://lnkd.in/eRfuSXdS   ♻ You can read more about genOway's Low-Carbon Program here 👉 https://lnkd.in/en6Tw9Fg   #genowaylowcarbon #preclinicalresearch #preclinicalservices

We will present our poster 📰 ‘#BRGSF-HIS mice as a predictive tool for safety assessment of biologics’ 📰 at ESMO - European Society for Medical Oncology in Barcelona from September 13-17, 2024 👉 https://lnkd.in/efwrWy-r Fabiane Sônego, our Director - Preclinical Models & Services, who will present genOway's poster, would be delighted to connect and explore new opportunities for collaboration. Get more information on the ESMO 2024 congress here 👉 https://lnkd.in/eAye3rGx #esmo2024 #preclinicalmodels #cancerresearch

The double humanized HSA/FcRn mouse model is a valuable tool for preclinical development of HSA and FcRn-oriented therapeutics in a variety of fields, such as oncology, infectious diseases, and autoimmune diseases 👉 https://lnkd.in/eez9j8Xn It allows for a more translatable PK/PD of HSA and/or FcRn-binding molecules due to: ▶ A physiological expression and distribution of HSA and human FcRn ▶ A more physiological affinity of HSA to human FcRn ▶ An unaltered blood chemistry compared to a wild-type mouse This results in a more translatable half-life of compounds targeting HSA/FcRn than in a wild type mouse, as demonstrated 📰 by some of our partners: Check out Avacta’s poster 'Pharmacokinetic and Biodistribution of Formatted Affimer® Biotherapeutics Targeting PD-L1' here 👉 https://lnkd.in/eRXz9Hqr Check out Crescendo Biologics Limited’ poster 'CB307: A dual targeting costimulatory Humabody ® VH therapeutic for treating PSMA-positive tumors' here 👉  https://lnkd.in/eWEDEJSp #preclinicalmodels #preclinicalresearch #pharmacodynamics #pharmacokinetics

genOway's new humanized TFRC mouse model (hTFRC) is a valuable tool to assess compounds that need to be delivered to the central nervous system, as conjugation of therapeutic agents to molecules binding to TRFC, expressed along the blood-brain barrier (BBB), are being used to deliver drugs 👉 https://lnkd.in/e-RazTTV Shuttling of compounds through the BBB is possible thanks to the physiological expression of TFRC in the mouse, as well as its functional endocytosis. 🧠 Check out our poster in which we showed that anti-BACE1/anti-TFRC can cross the BBB and reduce amyloid-β levels in the brain, unlike an anti-BACE1 antibody that remained in the plasma 👉 https://lnkd.in/ez6q86aP #preclinicalservices #preclinicalresearch #preclinicalmodels